HLA Zygosity Increases Risk of Hepatitis B Virus-Associated Hepatocellular Carcinoma

Zhiwei Liu,Chih-Jen Huang,Yu-Han Huang,Mei-Hung Pan,Mei-Hsuan Lee,Kelly J. Yu,Ruth M. Pfeiffer,Mathias Viard,Yuko Yuki,Xiaojiang Gao,Mary Carrington,Chien-Jen Chen,Allan Hildesheim,Hwai- Yang

DOI: https://doi.org/10.1093/infdis/jiab207

2021-01-01

The Journal of Infectious Diseases

Abstract:Background. Diversity in the HLA genes might be associated with disease outcomes-the heterozygote advantage hypothesis. We tested this hypothesis in relation to hepatitis B virus (HBV)-associated hepatocellular carcinoma (MCC). Methods. We utilized DNA from > 10 000 Taiwanese individuals with current or past HBV infection to examine the association between HLA diversity and critical natural history steps in the progression from HBV infection to HCC. Individuals were classified as homozygotes at a given locus when imputed to carry the same 4-digit allele for the 2 HLA alleles at that locus. Results. Increase in number of homozygous HLA class II loci was associated with an increased risk of chronic HBV infection (P-trend = 1.18 x 10(-7)). Among chronic HBV carriers, increase in number of homozygous HLA class II loci was also associated with an increased risk of HBV-associated HCC (P-trend = .031). For individual HLA loci, HLA-DQB1 homozygosity was significantly associated with HCC risk (adjusted hazard ratio = 1.40; 95% confidence interval, 1.06-1.84). We also found that zygosity affects risk of HCC through its ability to affect viral control. Conclusions. Homozygosity at HLA class II loci, particularly HLA-DQB1, is associated with a higher risk of HBV-associated HCC.